
China’s NMPA Accepts NDA for Sintilimab Plus Fruquintinib in Second-Line Advanced/Metastatic RCC
China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) seeking the approval of sintilimab (Tyvyt) in combination with fruquintinib (Fruzaqla) for the treatment of patients with locally advanced or metastatic renal …